They found an enrichment of mutations associated with ABC-DLBCL (i.e., mutations in MYD88 and CD79B) and frequent rearrangements involving programmed cell death ligands 1 and 2 (PD-L1/PD-L2) [114]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.